The agreement resolved pending patent litigation involving GLUMETZA (extended release metformin tablets) 1000mg and 500mg.
According to the agreement, Lupin gains right to sell a generic version of GLUMETZA on 1 February 2016, or earlier under certain circumstances.
The settlement agreement is subject to review by the US Department of Justice and the Federal Trade Commission.
The agreement is also subject to entry by the US District Court for the Northern District of California of an order dismissing the litigation.